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EDITORIAL REVIEW
Escape from the sodium-retaining effects of mineralocorticoids:
Role of ANF and intrarenal hormone systems
Chronic exposure to either endogenous or exogenous mm-
eralocorticoid excess results in a syndrome characterized by
hypokalemia, metabolic alkalosis, polydipsia, polyuria, and
mild arterial pressure elevation. Contrary to what might be
expected from the mechanism of action of these hormones,
there is only a transient period of positive sodium balance (Fig.
1). The expansion of the extracellular fluid volume is main-
tained as evidenced by an increase in body weight even after
sodium balance is restored. However, this elevation of the
extracellular fluid volume is not striking, and congestive heart
failure is not part of the syndrome [1].
In 1950, Daughaday and MacBride evaluated the effects of
chronic deoxycorticosterone acetate (DOCA) administration
with varying sodium intakes on urinary sodium excretion [2].
They showed that when dietary sodium intake was held at 3
mEq per day the excretion of sodium was negligible throughout
the experiment. When the dietary sodium was changed to 203
mEq per day, there was a period of transient sodium retention
which was followed by a restoration of sodium balance. These
authors also made the important observation that while sodium
balance was restored, plasma potassium and sweat sodium
concentrations remained low, suggesting a sustained effect of
the mineralocorticoid's action. In 1952 Relman and Schwartz,
using a similar protocol in humans, also concluded that the
action of DOCA was sustained while sodium balance was
restored [3]. The term "escape" was thus introduced into the
literature to describe the regulatory mechanisms which are
responsible for overriding the continued sodium-retaining ef-
fects of mineralocorticoids. The term is appropriate, and this
review will use "escape" as an abbreviation when referring to
this phenomenon.
In 1980 our group summarized what was known about escape
[4]. The view was expressed that expansion of the effective
vascular volume induced by salt and water retention constitutes
the central event responsible for triggering the mechanisms that
mediate escape. The resulting increase in arterial blood pres-
sure then leads to increased sodium excretion through intrare-
nat mechanisms similar to those activated by pressure natriure-
sis [5]. There was at that time evidence indicating that escape
could not be explained solely by the pressure natriuresis
mechanism. The existence of a modulatory mechanism capable
of sensing volume expansion and evoking a natriuresis by
altering renal function in the absence of proportional incre-
ments of either cardiac output or blood pressure had been
suggested [6]. We attributed this modulatory role to cardiac
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pulmonary receptors since they were shown to be activated by
atrial stretch in proportion to increases in end diastolic pressure
[71 and volume expansion [8]. The participation of humoral
factors was minimized because no information was available on
their chemical constitution or their possible site of origin [9]. It
is now clear that atrial natriuretic factor [10], in addition to
cardiac pulmonary receptors [61, is a major mechanism respon-
sible for the "central circulatory modulation" that facilitates
escape.
The central circulatory modulation is effectively integrated
with intrarenal mechanisms which regulate sodium excretion,
such as the renin-angiotensin system, the prostaglandin system,
and other renal autacoids [6]. It is the aim of this review to
examine the interactions between the circulatory and renal
modulatory mechanisms during escape, and to define their
relative importance.
Atrial natriuretic factor
In 1961 De Wardener et al elegantly showed that an acute
saline load caused an increased sodium excretion in dogs whose
glomerular filtration rate and mineralocorticoid levels were
controlled [11]. They concluded from cross-circulation experi-
ments that the observed natriuresis was due to a humoral agent.
Thus began a twenty year quest for a natriuretic factor. In 1980
we remained skeptical and stated that the search for a natri-
uretic hormone was not obligatory [4]. Nonetheless, the search
went on, and at least one such hormone has been discovered.
Indeed, in 1981 DeBold et al reported that the intravenous
injection of myocardial extracts elicited a rapid and potent
natriuretic response in rats [10]. Barely six years after this
finding, a long sought-after natriuretic factor has been isolated,
characterized, and made commercially available; radioimmu-
noassays for it have been developed, and a myriad of informa-
tion about it has emerged under many different names. A recent
consensus opinion indicates that the term "atrial natriuretic
factor" (ANF) is the favored trivial name, and it shall be used
to allude to it [12]. The reader is referred to recent reviews for
more detailed information about ANF [13—16]. This review will
focus on the possible role of ANF in escape.
Stretch of the atria is the principal stimulus for the release of
ANF [171. In conditions of extracellular volume expansion the
atrial pressures increase, the atria are stretched, and ANF is
secreted [18]. Since chronic mineralocorticoid excess with
normal or high sodium intake is characterized by extracellular
fluid expansion, ANF became a likely candidate to contribute to
escape. Indeed, within the past two years, ANF levels have
been reported to be elevated during escape in the rat [19, 20],
dog [21, 22], pig [23], and human [24—26].
Grekin, Terris and Bohr developed a model of chronic DOCA
administration in pigs [27]. Using this model, which includes the
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________________
one depot injection of DOCA. By the third and fourth collection
________________
periods, at 48 and 72 hours post-injection, respectively, potas-
sium excretion levels had returned to control levels. This
suggests that DOCA levels were decreased. Thus, it is difficult
to ascertain that these animals were actually in escape. None-
theless, this paper clearly establishes that acute mineralocor-
ticoid administration causes an increased synthesis and release
of ANF. Metzler et al provided more insight into the source of
ANF during escape 1221. These authors demonstrated that atrial
mRNA levels were elevated in dog hearts on the fourteenth day
after beginning daily DOCA injections of 15 mg/day. Using blot
hybridization analysis, mRNA levels were found to be 3.9 nd
6.7 times higher for the left and right atria, respectively, than in
control dogs. UnfOrtunately, a temporal profile of ANF mRNA
could not be obtained. Nevertheless, this study suggested that
synthesis of ANF is increased late in escape,and added to the
previous study by Ballerman et al 119]. Thus, it is likely that the
observed elevated levels of plasma ANF are due to increased
synthesis of the peptide throughout the exposure to mm-
eralocorticoid excess, and not to release of previously synthe-
sized hormone.
Daily levels of plasma atrial natriuretic factor have been8 10
obtained by several investigators during mineralocorticoid ad-
ministration. Granger et a! showed that ANF concentrations
reached significantly higher levels 24 hours after aldosterone
treatment was begun in dogs [211. This profile matched in-
creases in cumulative sodium balance. In this study sodium
excretion returned to control levels on the fourth day after
aldosterone was begun, following the rise of plasma ANF
concentrations. Similar results by Metzler et al confirmed this
daily plasma ANF profile [221.
Temporal plasma ANF concentration profiles have also been
established in the human. Zimmerman et a! [24], Wambach et a!
[25], and Cappuccio et at [261 independently measured daily
ANF levels in normal human volunteers treated with fludrocor-
tisone acetate. In all studies plasma ANF levels increased along
with mean body weight. This suggests that an increased extra-
cellular fluid volume is responsible for the increased production
of ANF. Nonetheless, there are differences between the stud-
ies. Sodium intake varied from 150 [24] to 270 [26] to 300 [25]
mEq per day. The dose of 9-alpha fluorohydrocortisone was
also different at 0.8 [25] or 0.4 [24] mg per day, or 8.0 g x
day' x kg' [261. These differences may account for the
differing conclusions that the papers express. Zimmerman et a!
and Cappuccio et a! suggest that ANF may mediate escape,
since in their studies plasma ANF concentrations and cumula-
tive sodium balance curves closely parallel each other [24, 26].
Wambach et a!, on the other hand, suggest that ANF does not
seem to trigger the escape mechanism [25]. Three of their five
male subjects maintained a positive sodium balance for up to
five to seven days despite peak levels of ANF at an earlier
point. In this study it is likely that the high sodium intake
engaged the ANF system before the mineralocorticoid was
started. Indeed, plasma levels of ANF were much higher in this
study (55.7 pg/mI during control to 327.5 pg/mi on day 14) than
in those of Zimmerman et at (33 6 pg/mI during control to 55
14 pg/mI during escape to 83 20 pg/mI at peak levels) or
Cappuccio et al (6.5 1.1 pg/mt during control to 16.6 2.9 pg/
ml at day 9). Thus, the addition of an antinatriuretic compound
to a high sodium diet in the Wambach study may have
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Fig. 1. Effects of aldosterone infusion on mean arterial pressure,
cumulative sodium balance, and urinaty sodium excretion. Values
represent means + SE from five dogs (Adapted from Ref. 91).
subcutaneous implantation of silicone strips impregnated with
DOCA, they found that immunoreactive atrial natriuretic 'hor-
mone' goes up following implantation [231. Unfortunately, this
paper did not provide sodium excretion data and a temporal
profile between sodium excretion and plasma ANF levels was
not established. What this paper does offer that others do not is
a temporal profile of central venous pressures. It is evident that
ANF levels increase in parallel with central venous pressures
through the third day following implantation. A plateau in both
curves is seen beginning on the fourth day after implantation.
Thus, this paper lends strong support to the concept that
mineralocorticoid treatment leads to increases in ANF through
increments in extracellular fluid volume, central venous pres-
sure, and atrial stretch.
Luft et al showed that immunoreactive atrial natriuretic
factor in atrial tissue does not change in Wistar rats as late as 72
hours after beginning treatment with DOCA [28]. Thus, it is
unlikely that release of previously stored ANF contributes to
the response to mineralocorticoid administration. More likely,
the increased plasma ANF concentrations following mm-
eralocorticoid administration are due to increased synthesis of
the hormone [19, 22]. By use of dot hybridization analysis and
cDNA probes, Ballerman et al showed an increased ratio of
pre-pro-ANF mRNA to A50 mRNA in rat atria as early as 12
hours after the subcutaneous injection of a 10 mg DOCA bolus
119]. In this study plasma immunoreactive ANF concentrations
were also increased at 12 hours, paralleling the changes in the
pre-pro-ANF mRNA to A50 mRNA ratio. These findings indi-
cated that the rise in ANF levels that followed DOCA injection
was due at least in part to an increased synthetic rate of the
hormone. However, the rats in these experiments received only
Gonzalez-Ca'npoy et a!: Mineralocorticoid escape 769
110
u 100
80
aG; 60>Q 40
CD 20E 0
—20
masked an underlying natriuretic response to increased levels
of ANF.
From the available studies on ANF during mineralocorticoid
administration, some conclusions may be drawn. It is possible
that DOCA directly stimulates the synthesis of ANF in atrial
myocytes [19]. More likely, sodium retention due to mm-
eralocorticoid action causes an expansion of the extracellular
fluid volume, including the intravascular volume. The increased
venous volume results in increments in central venous pressure
[27]. This increased pressure results in atrial stretch that is
higher in the right than in the left atrium [23]. Stretch of the
atrial myocytes is somehow translated to a chemical stimulus
that leads to increased transcription and translation of the ANF
genetic material [19]. Synthesis of new ANF is maintained as
long as the atrial stretch is maintained [22, 23]. Thus, levels of
ANF in the plasma rise as sodium retention progresses [19, 21—
25] (Fig. 2). There is conflicting evidence as to the exact
temporal profile of ANF plasma levels and sodium excretion.
These conflicts may be attributed to: differences in species or
strains; sodium intake; mode of administration, choice, and
dosage of the mineralocorticoid; and ANF assay techniques
used in the assorted investigations. Nonetheless, it seems that
ANF levels begin to rise before sodium excretion returns to
control levels in most studies. This evidence supports the
concept that ANF may play a role in escape.
Unfortunately, the precise role of ANF during chronic mm-
eralocorticoid administration remains unknown. In all likeli-
hood this question will remain largely unanswered until an
antagonist to ANF is used in escape. Nonetheless, the putative
role of ANF in escape may be analyzed in terms of what is
known from related observations. The two major effects of
ANF are to block antinatriuretic mechanisms and to stimulate
natriuretic pathways. Analyzing each of these two effects
during chronic mineralocorticoid administration may help elu-
cidate the role of ANF in escape.
ANF inhibits aldosterone production in vitro and in vivo [29,
30]. ANF is also known to be a strong inhibitor of renin
secretion [311 and therefore of angiotensin II as well. However,
in conditions of exogenous administration or excess endoge-
nous production of mineralocorticoids, the effects of ANF on
their synthesis would be negligible since the plasma levels of
mineralocorticoids in these two conditions would be fixed at
abnormally high levels. Therefore, if ANF contributes to es-
cape it does so by triggering natriuretic mechanisms directly or
indirectly. Such effects have been described in acute studies, as
stated in recent reviews [13—16]. Directly, ANF has been shown
to increase lithium clearance, suggesting an inhibition of prox-
imal tubular sodium reabsorption of the kidney as a whole [31,
32]. This observation is supported by studies of Hammond,
Yusufi and Knox on cortical proximal tubule brush border
membrane vesicles isolated from ANF-pretreated rats [33].
These authors demonstrated that the inhibition of sodium-
coupled transport processes in proximal tubules is an integral
part of the renal response to ANF. ANF also affects epithelial
sodium transport in the inner medullary collecting duct, and this
may, indeed, be its principal site of action through a cGMP-
mediated response [13, 34], In addition to these direct effects,
ANF, as will be discussed later, decreases the synthesis of
angiotensin II by inhibiting renin release [311. This leads to a
decreased proximal sodium reabsorption and a proportionately
greater efferent than afferent arteriolar vasodilation, two indi-
rect effects of ANF that may be important in escape.
Evidence suggesting that chronic elevations of ANF in es-
cape led to a down regulation of its receptors comes from
studies on renal glomerular ANF-receptor densities [19, 20].
The recruitment of additional circulating ANF molecules, at
least by glomeruli, seems not to be a likely event in escape.
Nonetheless, a natriuresis due to an increased post-receptor
response to ANF is still a possibility. Additionally, receptor
densities at various tubular sites of superficial and deep neph-
rons during escape need to be assessed. ANF is almost cer-
tainly acting at renal sites other than the glomerulus during
escape.
In addition to its natriuretic properties, ANF may play a role
in counteracting the increased blood pressure seen in escape.
The findings of Granger et al showed that the chronic adminis-
tration of ANF to normal animals causes a prominent chronic
decrease in mean arterial pressure, from 90 3 mm Hg during
control, to 74 3 and 75 4 mm Hg by days 4 and 5 of the ANF
infusion [35]. Thus, this study suggests that a possible role for
ANF in chronic mineralocorticoid excess may be to ameliorate
the increases in arterial pressure caused by volume expansion.
Since ANF causes a prominent venodilation which leads to
decreased cardiac preload and cardiac output, it seems likely
that its negative effect on blood pressure is not due to a change
in peripheral resistance [36].
Further studies are needed to precisely establish the contri-
bution of the elevated levels of atrial natriuretic factor observed
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Fig. 2. Effects of aldosterone infusion for 6 days on plasma levels of
atrial natriuretic peptide (ANP), cumulative sodium balance, and
sodiu,n excretion in 6 conscious dogs maintained on a fixed sodium
intake of 60 mEqlday, P < 0.05 (adapted from Ref. 21).
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in chronic mineralocorticoid excess to the natriuresis responsi-
ble for escape.
Renal adrenergic system
This section will focus on the seeming redundancy of having
both neural and hormonal natriuretic mechanisms activated in
escape. We refer the reader to a thorough, recent review on the
contribution of sympathetic renal reflexes to escape [37].
The threshold of changes in diastolic pressure needed to
stimulate cardiopulmonary receptors (CPR) is known to be well
within the range of pressure seen during a mild volume expan-
sion [381 which does not affect systemic pressure [39]. It is now
known that the same magnitude of changes in diastolic pressure
can stimulate the release of ANF [40,41]. No experiments have
been performed to determine if CPR and ANF have distinct
actions. There are, however, studies that, because of their
intrinsic designs, allow some useful speculation on the specific
role played by CPR in escape.
The selective stimulation of vagal non-myelinated afferent
fibers produces a strong sympathetic withdrawal with a de-
crease in cardiac rate and blood pressure [42]. It is known that
the sympathetic withdrawal that follows the stimulation of CPR
is rather specifically directed to the kidney [43]. These powerful
effects of CPR on renal resistance at very low stimulation
frequencies arise even during mild volume expansion [44].
The decrease of sympathetic renal nerve activity may ac-
count not only for renal vasodilation through a decreased
stimulation of alpha-adrenoreceptors, but also for a decrease in
renin release via decreased beta-adrenoreceptor stimulation
[45]. In fact, CPR exert a tonic inhibition on renin release.
Interruption of CPR nerve activity by vagal cooling produces an
immediate increase in renin release [46]. Additionally, there is
evidence for a direct antinatriuretic effect of the renal nerves on
the proximal tubule [47]. Decreased renal nerve activity would
thus facilitate a natriuresis. All the above mentioned effects can
be ascribed to a direct participation of CPR and renal nerves
independent of changes of ANF.
It has been suggested that ANF is also capable of decreasing
sympathetic activity [47, 48]. Recently Holtz, Sommer and
Bassenge demonstrated that the intravenous infusion of human
a-atrial natriuretic peptide inhibits the release of norepineph-
rifle and epinephrine [49]. The amounts of these catecholamines
that reached circulating levels were much lower than when
similar decrements of arterial pressure were induced by hydral-
azine or nitroglycerin [49]. Why is there a need for the organism
to activate neural and hormonal mechanisms which are in-
volved in regulating virtually the same processes during volume
expansion? The answer to this question could be found in the
functional modalities of neural and hormonal regulatory mech-
anisms. It is well known that neural mechanisms participate in
short-term regulation, whereas humoral responses are involved
in long-term regulation [6]. CPR therefore exhibit a predomi-
nant modulatory effect in conditions where a fast response to a
mild volume expansion is needed. This stimulation would fail to
evoke a sufficient elevation in circulating levels of ANF [28, 50]
at a rate necessary to counteract the possible elevation of
cardiac output and blood pressure. Under these conditions the
renal vasorelaxation, the decrease of renin release, and to a
certain extent a mild natriuresis could be mainly due to a neural
response. If the volume expansion continued, then nerve activ-
ity is likely to be reset in the same fashion as that seen for the
carotid baroreceptors [5]. Humoral responses would then be-
come important. Experimental studies to define the time period
required for cardiopulmonary receptor resetting need to be
performed, and the relative contributions of ANF and CPR to
the central circulatory modulation of escape need to be estab-
lished.
In addition to the central circulatory modulation by ANF and
central baroreceptor stimulation, escape is characterized by
intrarenal modulatory changes. The intrarenal modulation of
escape will be the subject of the following sections.
Renin-angiotensin system
Angiotensin is known to be a powerful sodium-retaining
hormone by a direct tubular effect on the proximal nephron
[51]. Thus, it is directly antinatriuretic besides causing hemo-
dynamic changes that indirectly lead to sodium retention. It is
now well established that angiotensin II levels are exquisitely
controlled by renin, so that increased renin stimulates angio-
tensin II formation [52]. Conversely, when renin levels are low,
angiotensin II levels decrease.
Mineralocorticoid excess leads to a decline of plasma renin
activity (PRA), an observation known for many years and
recently confirmed [21, 24, 26, 28]. Thus, there is a concomitant
decline in angiotensin II levels. In escape there are several
possible mechanisms whereby decreased renin activity may be
the outcome. First, the well known inverse relationship be-
tween renal perfusion pressure and renin release undoubtedly
plays a role in conditions of mineralocorticoid excess. As the
extracellular fluid volume expands due to the mineralocorticoid
action, renal perfusion pressure increases and renin release
declines. Second, ANF is known to inhibit renin release [31].
Indeed, a decline in PRA as plasma ANF levels rise is observed
during mineralocorticoid administration [21, 24, 26, 28]. Third,
mineralocorticoid excess and extracellular fluid volume expan-
sion lead to decreased renal sympathetic nerve activity [37].
Since the renal sympathetics stimulate renin release [53], there
is a lack of this stimulation.
All the above implies that escape is characterized by de-
creased levels of intrarenal angiotensin II. This decrease in turn
is reflected at the proximal tubule as a diminished sodium
reabsorption, and the result is a natriuresis. However, the few
studies that have characterized the role of the decreased levels
of angiotensin II in escape find that this contribution to escape
is negligible [54—56]. Biollaz et al studied mineralocorticoid
escape during angiotensin converting enzyme (ACE) inhibition
in the human [56]. If a decreasing amount of angiotensin II, as
suggested by decreasing PRA, was responsible for escape, then
ACE inhibition should accelerate escape. However, in this
study the time course of escape was not affected. The possibil-
ity remained, however, that intrarenal angiotensin II could
contribute to escape. Opgenorth et al [54] and Dickstein et al
[55] both studied the effects of intrarenal angiotensin II admin-
istration during escape. Both investigators expected that the
increased, fixed levels of intrarenal angiotensin II in these
experiments would slow down the escape phenomenon, since
the antinatriuretic effects of angiotensin II would counteract the
natriuretic mechanisms of escape. However, both groups found
that the administration of intrarenal angiotensin during mm-
eralocorticoid administration did not affect the time course of
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escape. Nonetheless, as reported by Opgenorth et at, maintain-
ing intrarenal angiotensin levels during mineralocorticoid ex-
cess results in a further increase in mean arterial pressure [54].
Thus, as they suggested, angiotensin II may be a determinant of
the magnitude of increase in arterial pressure required to
achieve escape.
Despite the lack of evidence making decreased renin activity
and angiotensin II levels major contributors to escape, the
absence of antinatriuretic and vasoconstrictive effects of this
system must be kept in mind as facilitators of the multiple
mechanisms that return sodium excretion to normal. The ab-
sence of both of these effects of angiotensin II may shift the
pressure natriuresis curve to the left. A shifted curve would not
affect the time course of escape, but it would allow a natriuresis
to begin at lower perfusion pressures.
Renal autacolds
It is well established that the levels of urinary prostaglandins
and kallikrein rise with chronic mineralocorticoid excess [4, 58—
62] (Fig. 3). A distinct protective role against hypokalemia has
been ascribed to these compounds [59, 63]. Decreased concen-
trations of plasma potassium increase renal kallikrein activity
[64]. This increased enzymatic activity results in an increase in
renal kinins [65], which in turn stimulate renal prostaglandin
production [60, 66]. The increased prostaglandin synthesis then
compensates for the hypokalemia by increasing renal water loss
[59, 64], This sequence has been confirmed by use of prosta-
glandin synthetase inhibitors [58, 59, 67—69], ACE inhibitors
[60], kallikrein inhibitors [64, 66], and potassium replacement
[59].
The role of the renal autacoids in the escape from the sodium
retaining effects of mineralocorticoids, however, remains con-
troversial, Some studies favor a role of prostaglandins and/or
kinins in escape [58, 62], yet others imply that these systems
don't contribute to it [59, 68]. The controversy surrounding the
effect of these compounds on sodium metabolism during escape
stems in all likelihood from the variety of experimental designs
used. For example, prostaglandin inhibition during escape leads
to a further increase in sodium retention [58]. In the human, this
change is evident when the mineralocorticoid used is 9-alpha-
fludrocortisone [58], but not when DOCA is administered [68].
This may be a reflection of the more potent pressor action of
9-alpha-fludrocortisone compared to DOCA [67]. Thus, the
ability of a given mineralocorticoid to increase renal perfusion
pressure may be the major determinant of the role of prosta-
glandins in escape. This conclusion follows from numerous
studies which point to the renal prostaglandins as important
intrarenal modulators of the pressure natriuresis phenomenon.
Acute blockade of prostaglandin synthetase results in a blunted
natriuretic response to increases in renal perfusion pressure
[70]. Although prostaglandins are not essential for the basic
manifestation of pressure natriuresis [71], they are important
modulators of this phenomenon [70, 71]. Prostaglandin synthe-
sis is stimulated by increased perfusion pressure [72], as well as
by increased renal interstitial hydrostatic pressure [73]. Recent
studies by Pawlowska et at in rats showed that a renal intersti-
tial volume expansion which led to increases in renal interstitial
hydrostatic pressure also produced a natriuresis [73]. In this
study, prostaglandin blockade blunted the observed natriuresis
despite similar increases in renal interstitial hydrostatic pres-
sure. The authors concluded that prostaglandins are necessary
for the full expression of the renal interstitial pressure-induced
natriuresis. Thus, acute prostaglandin synthesis leading to a
natriuresis seems to be intimately related to renal hemodynamic
stimuli which are present in escape, as will be discussed later.
The renal autacoids have many other actions, but a discus-
sion of them is beyond the scope of this paper. We refer the
reader to recent reviews for a more detailed discussion of their
actions [74, 75]. In light of their well-known natriuretic proper-
ties acutely [76, 77], and their elevated levels during mm-
eralocorticoid excess, the renal autacoids remain as likely
candidates to contribute to escape. However, their precise role
as modulators in escape remains to be elucidated, especially as
it refers to the pressure natriuresis phenomenon.
The role of hemodynamic and physical factors
Increased renal interstitial hydrostatic pressure (RIHP) has
been postulated as a crucial mediator of the natriuresis that
follows increases in renal arterial pressure within the autoreg-
ulatory range [78—80]. Acute experiments clearly demonstrate
that increases in peritubular capillary hydrostatic pressure and
RIHP are accompanied by elevations in sodium excretion [81—
831. Furthermore, in conditions of renal vein constriction, acute
saline volume expansion, acute intrarenal aortic ligation, intra-
renal infusion of vasodilators, acute renal lymphatic ligation, or
direct renal interstitial volume expansion, the increases in
RIHP are paralleled by increases in the fractional excretion of
sodium [84—89].
Burnett, Haas and Larson demonstrated that mineralocor-
ticoid escape is associated with increased RIHP [90] (Fig. 4). In
experiments done on DOCA-treated rats, micropuncture stud-
ies were performed once the animals were in escape. Elevations
were demonstrated in arterial pressure, superficial peritubular
capillary hydrostatic pressure and vasa recta hydrostatic pres-
sure. Clearly then, the same hemodynamic natriuretic mecha-
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Fig. 3. The effect of DOCA on urinary sodium and prostaglandin
excretions in 6 female dogs (Adapted from ref. 59).
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nisms that operate under acute conditions are activated during
escape. The elevation in arterial pressure brought about by
expansion of the extracellular fluid volume during escape was
likely responsible for the observed increases in capillary hydro-
static pressures. The latter then increased RIHP, decreased the
reabsorption of sodium and resulted in a natriuresis.
Hall et al in 1984 studied the relationship between renal
arterial pressure and the renal handling of sodium during escape
[91] (Fig. 5). They demonstrated that an increase in renal
arterial pressure was necessary for the kidneys to escape. By
means of an electronically servo-controlled suprarenal aortic
cuff they were able to control the perfusion pressure to the
kidneys. In dogs where there was no attempt to control the
renal arterial pressure, escape occurred as predicted. On the
other hand, in those animals whose renal arterial pressure was
not allowed to increase with the mineralocorticoid-induced
volume expansion, escape did not occur. Those animals expe-
rienced a continued sodium retention with a rise in mean
arterial pressure and ascites formation. When the renal arterial
pressure was subsequently allowed to increase, the dogs in-
creased their sodium excretion and eventually returned to
normal sodium balance. It is of interest to note that in this
experiment renal arterial pressure was not only prevented from
rising, but actually was slightly decreased compared to baseline
levels. It is possible that this slight decrement was sensed in the
tubular microenvironment and that further antinatriuretic sys-
tems, such as renin-angiotensin, were activated intrarenally.
Additionally, systemic natriuretic mechanisms such as atrial
natriuretic factor, which was not measured in this experiment,
may have been unable to exert their effects. This is suggested
by recent studies of Davis and Briggs who showed that reduc-
tions in renal arterial pressure block the natriuretic and diuretic
effects of ANF [92], and of Paul, Kirk and Navar who suggested
this blockade of the action of ANF is due to an effect on tubular
sodium reabsorption [93]. Nonetheless, the findings by Hall et
al suggested that arterial pressure changes are prime determi-
nants of escape.
Intrarenal hemodynamic changes resulting from changes in
perfusion pressure are intimately related not only to renal
interstitial hydrostatic pressure, but to the tubuloglomerular
feedback (TGF) as well. The papers regarding TGF in escape
have shown that the chronic administration of mineralocor-
ticoid and salt blunt it [94—97]. This would be expected, since
there is evidence that extracellular fluid volume expansion may
lead to a resetting of the TGF [98]. The TGF blunting seems to
depend on the effective expansion of the extracellular fluid
volume. Evidence for this dependence comes from the work of
Moore et al, who found that the administration of furosemide
restores TGF within one hour [94]. Thus, TGF resetting may be
another intrarenal mechanism facilitating the return to sodium
balance in escape.
One additional observation regarding renal hemodynamics
during escape was made by Dusing et al [99]. These investiga-
tors measured papillary tissue osmolality and sodium concen-
tration during escape from DOCA-induced sodium retention.
They found that both parameters were significantly decreased
compared to control measurements. This study fits in well with
observations regarding the increased medullary blood flow
caused by ANF [100] and prostaglandins [75]. A decrement in
papillary osmolality is likely to be due to the "washout" of the
medullary interstitium caused by increased blood flow to this
area. In turn this would lead to decreased water reabsorption by
the descending limb of the 1oop of Henle, and perhaps contrib-
ute to the ensuing diuresis and natriuresis.
Nephron segments responsible for escape
It is now well established that the nephron site of mm-
eralocorticoid action is the principal cell population of the
cortical collecting tubule [101]. O'Neil and Helman, and
Schwartz and Burg, showed that during escape mineralocorti-
coids continue to act on this segment, as evidenced by a
sustained, enhanced sodium reabsorption [102, 103]. Therefore,
the nephron site(s) responsible for escape are different from the
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site of action of mineralocorticoids. However, there is still
considerable controversy with respect to the segment(s) that
are indeed responsible for the rejection of sodium during
escape.
Part of the controversy surrounding the precise site of escape
is due to the limitations inherent in the use of micropuncture
techniques [104] and the heterogeneity of nephron populations
in the handling of sodium [105]. Earlier micropuncture studies
used only available superficial sites for sampling, which in-
cluded the proximal convoluted tubule and the distal tubule of
superficial nephrons. Whole-kidney techniques, on the other
hand, measured the total contribution of superficial and deep
nephron populations as well as the collecting system.
Piecing the individual known sites of action for each of the
possible contributors to escape may help to clarify the nephron
sites responsible for the decreased sodium reabsorption leading
to escape. Even though the subject is still controversial, there is
evidence that pressure natriuresis is due to decreased proximal
tubule sodium reabsorption of deep but not superficial nephrons
[105]. Additional studies have shown that ANF may have a
direct tubular effect at the proximal tubule [31, 32], and at the
medullary collecting duct [14]. It is also known that the lack of
renal sympathetic nerve activity and the decreased levels of
angiotensin II may lead to a decreased proximal tubular sodium
reabsorption [21, 24, 37]. Finally, medullary "washout" is
known to affect the loop of Henle [591.
Kohan and Knox studied nephron heterogeneity of sodium
reabsorption in DOCA treated rats using micropuncture [106].
They sampled from late proximal and early distal superficial
segments, and from late proximal and deep ioop of Henle
segments. They found that fractional reabsorption of sodium is
diminished in the superficial nephron segment containing the
pars recta and ioop of Henle, and in the deep nephrons proximal
to the bend in Henle's loop. Their data suggested that the pars
recta and/or descending loop of Henle is a site contributing to
the decreased sodium reabsorption leading to escape. These
findings supported those of Schacht, Lowenstein, and Baldwin,
who, using free-water clearance studies suggested that a prox-
imal site is responsible for escape [107]. Further evidence
implicating the proximal tubule comes from a study of Boer,
Koomans and Dorhout-Mees [108]. These investigators found
that lithium clearance, a marker of proximal tubule sodium
reabsorption, was increased during escape. However, they
failed to establish a temporal relationship between changes in
sodium and lithium reabsorption. In their protocol they sampled
subjects twice, once before the administration of fludrocorti-
sone acetate and again when they were judged to be in escape.
This study is consistent with previous observations suggesting
that whole kidney proximal tubular sodium reabsorption is
decreased during escape.
The proximal tubule may be only one of several sites con-
tributing to escape. Massry et al reported in 1968 that escape is
associated with a hypercalciuria and hypermagnesiuria [109].
Independently, Suki et al demonstrated the same phenomenon
for calcium only [110]. Both groups concluded that a decreased
proximal tubular reabsorption of the cations, with increased
distal delivery of all, was responsible for their observations.
Rastegar et al expanded on these observations in 1972 [111]. In
studies on seven patients with primary aldosteronism and three
normal volunteers they confirmed that escape is characterized
by a hypercalciuria. However, they also measured phosphate
excretion and found that it was unchanged between controls
and patients in escape. Furthermore, they found that whereas
the clearance of calcium was highly related to the clearance of
sodium, the clearance of phosphate was not. Their data thus
suggested that distal and not proximal nephron sites were the
ones contributing to escape. Alternatively, phosphate clear-
ances, particularly in the absence of control by hormones
affecting phosphate reabsorption, may be a poor marker for
sodium reabsorption by the proximal tubule. More recently,
Gehr and Goldberg attempted to better characterize the sites
responsible for the hypercalciuria of escape using clearance and
micropuncture techniques [112]. Since the increased excretion
of calcium was significantly reduced by hydrochlorothiazide
and amiloride and was independent of parathyroid hormone,
and since the punctured nephron segments showed no calcium
rejection, these authors concluded that calcium reabsorption is
most likely to occur in the terminal nephron. However, as they
have recognized, the sites they punctured were only superficial,
and deep and superficial proximal tubules behave differently
during escape.
Additional support for a contribution of the terminal nephron
to escape was provided by studies of Dusing et al [99]. In
studying the inner medullary osmolality and sodium concentra-
tion of DOCA-treated rats during escape, and comparing them
to furosemide treated rats, they found they were similar. They
reasoned that if furosemide, an inhibitor of sodium chloride
reabsorption by the ascending loop, gave measurements similar
to those seen in escape, then escape could be due to inhibition
of ascending loop transport. Thus, they concluded that medul-
lary portions of the distal tubule contribute to escape. This
analogy may not be entirely appropriate since we know from
the study that at least one parameter that was measured, the
inner medullary potassium concentration, was different be-
tween the two groups. Furthermore, escape is a chronic condi-
tion, and comparing it to acute furosemide administration does
not acknowledge this fact. Nonetheless, it is likely that seg-
ments in addition to the proximal tubule are involved in escape.
In summary, data has accumulated that lends strong support
to a role of the proximal tubule in the decreased sodium
reabsorption that leads to escape. The contribution of other
nephron segments, principally the thick ascending limb of
Henle is likely. The medullary collecting duct remains a candi-
date for contributing to the escape phenomenon since ANF is
known to have a direct tubular effect in this segment.
Conclusion
A number of interrelated mechanisms modulate the response
that leads to escape (Fig. 6). The time course of escape is
dependent on the conditions under which mineralocorticoid
action leads to extracellular fluid volume expansion. The basic
hemodynamic changes of pressure natriuresis following chronic
volume expansion are needed for the expression of the central
circulatory modulation of ANF and sympathetic withdrawal.
Intrarenal modulation by the renal prostaglandins and a de-
creased antinatriuretic action of angiotensin II are likely to
contribute to escape. The intrarenal modulatory mechanisms in
escape need to be further defined. Escape from the sodium-
retaining effects of mineralocorticoids is due to the decreased
sodium reabsorption of nephron segments other than those of
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mineralocorticoid action. The decreased reabsorption of so-
dium, especially by the proximal tubule, results in increased
distal delivery of the cation, overcoming the sustained effect of
the mineralocorticoid. The discovery of ANF has greatly added
to our understanding of escape. Its precise role as it interrelates
with the other modulatory mechanisms of escape needs further
investigtttion.
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